Telix Pharmaceuticals (TLX) Receivables - Net (2023 - 2024)
Telix Pharmaceuticals (TLX) reported Receivables - Net of $91.3 million for Q4 2024, up 116.58% year-over-year from $42.2 million in Q1 2024, and up 116.58% quarter-over-quarter from $42.2 million in Q4 2023.
Telix Pharmaceuticals (TLX) Receivables - Net (2023 - 2024) Analysis & Trends
Telix Pharmaceuticals (TLX) has 2 years of Receivables - Net data on file, last reported at $91.3 million in Q4 2024.
- Receivables - Net for Q4 2024 came in at $91.3 million, up 116.58% year-over-year; the trailing twelve-month figure through Dec 2024 was $91.3 million (up 116.58% YoY), and the FY2024 annual result was $84.6 million, up 92.01% from the prior year.
- Receivables - Net advanced to $91.3 million in Q4 2024 per TLX's latest filing, from $42.2 million in the prior quarter.
- Over five years, Receivables - Net peaked at $91.3 million in Q4 2024 and troughed at $42.2 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Telix Pharmaceuticals | 4.81 Bn | 4.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 91.33 Mn |
| Dec 31, 2024 | 91.33 Mn |
| Dec 31, 2023 | 42.17 Mn |
| Dec 31, 2023 | 42.17 Mn |